Clinical research company Fortrea Holdings (NASDAQ: FTRE) fell short of the market’s revenue expectations in Q1 CY2025, with sales falling 1.6% year on year to $651.3 million. Its non-GAAP profit of $0.02 per share was significantly above analysts’ consensus estimates.
Is now the time to buy FTRE? Find out in our full research report (it’s free).
Fortrea (FTRE) Q1 CY2025 Highlights:
- Revenue: $651.3 million (1.6% year-on-year decline)
- Adjusted EPS: $0.02 vs analyst estimates of -$0.07 (significant beat)
- Adjusted Operating Income: $16.43 million vs analyst estimates of $12.79 million (2.5% margin, 28.5% beat)
- EBITDA guidance for the full year is $185 million at the midpoint, above analyst estimates of $172.7 million
- Operating Margin: -79.9%, down from -5.6% in the same quarter last year
- Market Capitalization: $419.2 million
StockStory’s Take
Fortrea’s first quarter results were shaped by ongoing transformation efforts and the lingering effects of late-stage clinical service bookings prior to the company’s spin-off. CEO Tom Pike attributed the modest revenue decline to a project mix weighted toward longer-duration oncology studies and delays in biotech project startups. Management also pointed to improved operational execution following the divestiture of the Enabling Services business and the exit from transition service agreements. CFO Jill McConnell highlighted that direct personnel costs were reduced significantly through an 8% reduction in permanent headcount, helping offset some revenue softness. However, general and administrative expenses increased due to investments needed to support Fortrea as a standalone public company.
Looking ahead, Fortrea’s leadership is focused on returning to revenue growth and expanding margins amid a challenging funding environment for biotech customers. Management reaffirmed annual guidance and expects that operating cash flow will improve as invoicing disruptions from the ERP system transition resolve. Interim CEO Peter Neupert, succeeding Tom Pike as part of a planned leadership transition, emphasized the company’s commitment to cost optimization and operational efficiency. Jill McConnell noted that ongoing margin improvement will depend on capturing targeted cost reductions and accelerating project burn rates, particularly in biotech and oncology. Management cautioned that macroeconomic and policy uncertainties, as well as delays in customer decision-making, could impact the pace of new business wins.
Key Insights from Management’s Remarks
Management attributed the softer revenue to project mix and slower biotech decision-making, while emphasizing progress on cost controls and operational independence post-spin.
-
Oncology Project Mix Impact: The company’s revenue burn rate was affected by a portfolio heavily weighted toward oncology trials, which typically progress more slowly due to study complexity, longer durations, and recruitment challenges.
-
Biotech Startup Delays: Decision-making delays among biotech clients, driven by funding uncertainties and a more cautious regulatory environment, contributed to slower project initiations. Management noted these delays have not resulted in cancellations but have extended proposal timeframes.
-
Operational Independence Achieved: Following the exit from transition service agreements tied to its former parent, Fortrea completed significant IT and personnel restructuring. The company reduced permanent headcount by 8% year over year and consolidated its systems and office footprint, supporting early cost savings.
-
Cost Reduction Initiatives: Management detailed $150 million in targeted gross cost reductions for 2025, focusing on both operations and SG&A (selling, general, and administrative expenses). Early progress includes reduced IT spend, a streamlined application portfolio, and facility optimizations.
-
AI and Technology Investments: Fortrea is deploying artificial intelligence tools, including Microsoft Copilot, to enhance productivity in areas such as protocol reviews and commercial workflows. These initiatives are expected to improve efficiency and reduce costs, though management acknowledged that human oversight remains essential due to regulatory requirements.
Drivers of Future Performance
Fortrea’s outlook hinges on cost discipline, pipeline execution, and customer funding dynamics, particularly in biotech and oncology segments.
-
Margin Expansion Focus: Management expects that margin gains will be driven by the realization of targeted cost reductions, including further SG&A optimization and increased project burn rates. The timing of savings is weighted toward the second half of the year as restructuring and automation initiatives reach full impact.
-
Biotech Market Uncertainty: The company’s ability to restart revenue growth depends on timely customer decision-making and improved funding access for biotech clients. Management cited a growing pipeline, but delays in biotech project starts remain a key risk to near-term growth.
-
Competitive Pricing and Project Mix: Fortrea aims to maintain pricing discipline in a competitive environment, especially as larger contract research organizations (CROs) increase their focus on biotech. The current portfolio’s mix of longer-duration and late-stage projects, particularly in oncology, is expected to moderate the pace of backlog conversion and revenue recognition.
Catalysts in Upcoming Quarters
Looking forward, key items to watch include (1) the pace of new project starts, particularly in biotech and oncology; (2) the company’s ability to realize its targeted cost reductions and improve SG&A efficiency; and (3) stabilization of cash flow and reduction of days sales outstanding following the ERP transition. Execution on commercial pipeline conversion and further technology-driven productivity gains will also be key markers of progress.
Fortrea currently trades at a forward P/E ratio of 9×. At this valuation, is it a buy or sell post earnings? See for yourself in our full research report (it’s free).
Now Could Be The Perfect Time To Invest In These Stocks
Market indices reached historic highs following Donald Trump’s presidential victory in November 2024, but the outlook for 2025 is clouded by new trade policies that could impact business confidence and growth.
While this has caused many investors to adopt a "fearful" wait-and-see approach, we’re leaning into our best ideas that can grow regardless of the political or macroeconomic climate. Take advantage of Mr. Market by checking out our Top 5 Strong Momentum Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today.